The final rose as did other trials in its space from the observation that breast cancer can be driven by mutations along the AKT PI3 kinase mTOR pathway and it’s one of a number of agents that tries to exploit that to the good of patients. So the final trial looked at capivasertib which inhibits all of the three types of AKT all of which may be important in cancer in a similar way to capivasertib it’s sort of a sister drug I guess so the FINER trial took a backbone of fulvestrant in the second line for ER positive HER2-negative cancer, in patients that all had a CDK4-6 inhibitor and an aromatase inhibitor, and that’s where it differed slightly from Capitello-291, where 70% had had CDK4-6 inhibitor, 30% had not...
The final rose as did other trials in its space from the observation that breast cancer can be driven by mutations along the AKT PI3 kinase mTOR pathway and it’s one of a number of agents that tries to exploit that to the good of patients. So the final trial looked at capivasertib which inhibits all of the three types of AKT all of which may be important in cancer in a similar way to capivasertib it’s sort of a sister drug I guess so the FINER trial took a backbone of fulvestrant in the second line for ER positive HER2-negative cancer, in patients that all had a CDK4-6 inhibitor and an aromatase inhibitor, and that’s where it differed slightly from Capitello-291, where 70% had had CDK4-6 inhibitor, 30% had not. And so it was a randomization, really, capivasertib versus placebo, so it was blinded. Patients have 21 days on and seven days off in the usual schedule of fulvestrant and then monitored obviously to progression or intolerance. So our findings certainly at the progression-free survival basis, the initial assessment of 15 months, we saw a significant difference and that was updated at 35 months and it remains significant. The progression-free survival moves out from 1.9 up to 5.4 months, both in the overall cohort and a very similar increase in the AKT PI3K altered cohort also.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
